Depression and rheumatoid arthritis Review article
Article Sidebar
Published:
Mar 31, 2020
Keywords:
tocilizumab, rheumatoid arthritis, depression, interleukin 6
Main Article Content
Abstract
Chronic pain, fatigue and progressive limitation of the patient’s ability to live independently cause dramatic deterioration in the quality of life in patients with rheumatoid arthritis (RA). The clearly more frequent occurrence of psychosomatic disorders among patients with rheumatoid arthritis may seem a simple consequence of the above aspects of this disease. The discovery of the role of pro-inflammatory cytokines, such as interleukin 6, interleukin 1, TNF-α or interleukin 17 in the development of depression, has created a space for seeking relationships between mood disorders and RA. The similarity of the profile of cytokines between depressive disorders and RA also gave hope for mitigating psychosomatic symptoms thanks to the use of anti-cytokine drugs. Tocilizumab, an antagonist of the IL-6 receptor, a key cytokine for the development of depressive disorders, has shown particular efficacy in this area, affecting not only a significant reduction in inflammatory activity, but also alleviating the symptoms of depression, often found in patients with rheumatoid arthritis..
Article Details
How to Cite
Guzera , Z., & Święcicki, Łukasz. (2020). Depression and rheumatoid arthritis. Medycyna Faktow (J EBM), 13(1(46), 74-80. https://doi.org/10.24292/01.MF.0120.8
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. van Hoogmoed D., Fransen J., Bleijenberg G., van Riel P.: Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010; 49: 1294-1302.
2. Atal S.A., Ceceli E., Okumu M. et al.: The evaluation of pain in patients with rheumatoid arthritis. Pain Pract. 2009; 9: 31.
3. Jacobi C.E., Mol G.D., Boshuizen H.C. et al.: Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services. Arth. Care Res. 2003; 49: 567-573.
4. Vallerand I.A., Patten S.B., Barnabe Ch.: Depression and the risk of rheumatoid arthritis. Curr. Opin. Rheumatol. 2019; 31(3): 279-284.
5. Gallagher P., Reid K.S., Ferrier I.N.: Neuropsychological functioning in health and mood disorder: modulation by glucocorticoids and their receptors. Psychoneuroendocrinology 2009; 34(supl. 1): S196-207.
6. Dougados M., Soubrier M., Antunez A., Hotopf M.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73(1): 62-68. DOI: 10.1136/annrheumdis-2013-204223.
7. Matcham F., Rayner L., Steer S.,Hotopf M.: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136-2148.
8. Covic T., Pallant J.F., Tennant A. et al.: Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet. Disord. 2009; 10: 18.
9. Kwiatkowska B., Kłak A., Raciborski F., Maślińska M.: The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study. Psychol. Health Med. 2019; 24(3): 333-343. DOI: 10.1080/13548506.2018.1529325.
10. Matcham F., Norton S., Steer S., Hotopf M.: Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 2016; 17: 224. DOI: 10.1186/s12891-016-1083-y.
11. Hepgul N., Mondelli V., Pariante C.M.: Psychological and biological mechanisms of cytokine induced depression. Epidemiol. Psichiatr. Soc. 2010; 19: 98-102.
12. Maes M., Anderson G., Kubera M., Berk M.: Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin. Ther. Targets 2014; 18(5): 495-512.
13. Kwiatkowska B., Kłak A., Maślińska M. et al.: Factors of depression among patients with rheumatoid arthritis. Reumatologia 2018; 56(4): 219-227. DOI: 10.5114/reum.2018.77973.
14. Hurst N.P., Kind P., Ruta D.: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 1997; 36: 551-559.
15. Farheen K., Agarwal S.K.: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J. Manag. Care Pharm. 2011; 17(9 suppl. B): S09-13.
16. DiMatteo M., Lepper H.S., Croghan T.W.: Depression is a risk factor for noncompliance with medical treatment:meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000; 160: 2101-2107.
17. Matcham F., Davies R., Hotopf M. et al.: The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register. Rheumatology 2018; 57(5): 835-843.
18. Marrie R.A., Hitchon C.A., Walld R. et al.: Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; 70: 970-978.
19. Deb A., Dwibedi N., LeMasters T. et al.: Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. Am. Health Drug Benefits 2019; 12(1): 30-38.
20. Li P., Zheng Y., Chen X.: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017; 8: 460.
21. Figueiredo-Braga M., Cornaby C., Cortez A. et al.: Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J. Immunol. Res. 2018: 5954897.
22. Maes M., Scharpe S., Meltzer H.Y. et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic- pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49: 11-27.
23. Choy E.H.S., Calabrese L.H.: Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford) 2018; 57: 1885-1895.
24. Navarro G., Taroumian S., Barroso N. et al.: Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin. Arthritis Rheum. 2014; 43: 458-469.
2. Atal S.A., Ceceli E., Okumu M. et al.: The evaluation of pain in patients with rheumatoid arthritis. Pain Pract. 2009; 9: 31.
3. Jacobi C.E., Mol G.D., Boshuizen H.C. et al.: Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services. Arth. Care Res. 2003; 49: 567-573.
4. Vallerand I.A., Patten S.B., Barnabe Ch.: Depression and the risk of rheumatoid arthritis. Curr. Opin. Rheumatol. 2019; 31(3): 279-284.
5. Gallagher P., Reid K.S., Ferrier I.N.: Neuropsychological functioning in health and mood disorder: modulation by glucocorticoids and their receptors. Psychoneuroendocrinology 2009; 34(supl. 1): S196-207.
6. Dougados M., Soubrier M., Antunez A., Hotopf M.: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73(1): 62-68. DOI: 10.1136/annrheumdis-2013-204223.
7. Matcham F., Rayner L., Steer S.,Hotopf M.: The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52: 2136-2148.
8. Covic T., Pallant J.F., Tennant A. et al.: Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales. BMC Musculoskelet. Disord. 2009; 10: 18.
9. Kwiatkowska B., Kłak A., Raciborski F., Maślińska M.: The prevalence of depression and insomnia symptoms among patients with rheumatoid arthritis and osteoarthritis in Poland: a case control study. Psychol. Health Med. 2019; 24(3): 333-343. DOI: 10.1080/13548506.2018.1529325.
10. Matcham F., Norton S., Steer S., Hotopf M.: Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis. BMC Musculoskelet. Disord. 2016; 17: 224. DOI: 10.1186/s12891-016-1083-y.
11. Hepgul N., Mondelli V., Pariante C.M.: Psychological and biological mechanisms of cytokine induced depression. Epidemiol. Psichiatr. Soc. 2010; 19: 98-102.
12. Maes M., Anderson G., Kubera M., Berk M.: Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin. Ther. Targets 2014; 18(5): 495-512.
13. Kwiatkowska B., Kłak A., Maślińska M. et al.: Factors of depression among patients with rheumatoid arthritis. Reumatologia 2018; 56(4): 219-227. DOI: 10.5114/reum.2018.77973.
14. Hurst N.P., Kind P., Ruta D.: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 1997; 36: 551-559.
15. Farheen K., Agarwal S.K.: Assessment of disease activity and treatment outcomes in rheumatoid arthritis. J. Manag. Care Pharm. 2011; 17(9 suppl. B): S09-13.
16. DiMatteo M., Lepper H.S., Croghan T.W.: Depression is a risk factor for noncompliance with medical treatment:meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000; 160: 2101-2107.
17. Matcham F., Davies R., Hotopf M. et al.: The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register. Rheumatology 2018; 57(5): 835-843.
18. Marrie R.A., Hitchon C.A., Walld R. et al.: Increased burden of psychiatric disorders in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2018; 70: 970-978.
19. Deb A., Dwibedi N., LeMasters T. et al.: Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. Am. Health Drug Benefits 2019; 12(1): 30-38.
20. Li P., Zheng Y., Chen X.: Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017; 8: 460.
21. Figueiredo-Braga M., Cornaby C., Cortez A. et al.: Influence of biological therapeutics, cytokines, and disease activity on depression in rheumatoid arthritis. J. Immunol. Res. 2018: 5954897.
22. Maes M., Scharpe S., Meltzer H.Y. et al.: Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic- pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49: 11-27.
23. Choy E.H.S., Calabrese L.H.: Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford) 2018; 57: 1885-1895.
24. Navarro G., Taroumian S., Barroso N. et al.: Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin. Arthritis Rheum. 2014; 43: 458-469.